Association between Treatment Response and Potential Indicators of Efficacy and Safety in a Phase III Trial of Decitabine in Older Patients with Acute Myeloid Leukemia

Awards Nomination 20+ Million Readerbase

Short Communication - (2015) Volume 6, Issue 1

Mark D. Minden¹^*, Christopher Arthur², Jiří Mayer³, Mark M. Jones⁴, Erhan Berrak⁴ and Hagop Kantarjian⁵: ¹Ontario Cancer Institute/Princess Margaret Hospital, Division of Stem Cell and Developmental Biology, Toronto, Ontario, Canada; ²Royal North Shore Hospital, Department of Haematology, St. Leonards, Australia; ³Masaryk University Hospital Brno, and CEITEC, Masaryk University, Czech Republic; ⁴Eisai Inc., Oncology Product Creation Unit, Woodcliff Lake, NJ, USA; ⁵The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, USA

^*Corresponding Author: